Today, we’re excited to spotlight three of our standout team members who help international and domestic brands navigate China’s complex trademark and unfair competition landscape.

In 2009, Jiaquan IP Law supported a U.S. medical device company entering China’s national phase through the PCT system. In October 2024, the patent faced a complete invalidation challenge in China.

Jiaquan is honored to join China’s first Overseas IPR Insurance Consortium, launched under the leadership of the Nanshan District Government in Shenzhen.

Going Global: How Medical Device Companies Can Align IP Protection with FDA Compliance, May 15, 9:00–10:30 AM China Time

This analysis provides a snapshot of legal trends shaping patent validity determinations during the reporting period.

In recent years, breakthroughs in artificial intelligence (AI) technology have emerged continuously, making it a significant driving force behind a new wave of technological revolution and industrial transformation.

At Jiaquan IP Law, we are committed to delivering results in intellectual property disputes. Here are two recent victories that showcase our strategic approach in patent enforcement and invalidation:

Facts of the Case